PMID- 31583900
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 15
IP  - 1
DP  - 2021 Jan
TI  - Assessment of the "Second Day" Exercise Effect on Glycemic Control, Insulin 
      Requirements, and CHO Intake in Type 1 Diabetes Adults.
PG  - 127-133
LID - 10.1177/1932296819879419 [doi]
AB  - BACKGROUND: Glucose control during consecutive days of aerobic exercise has not 
      been well studied. We assessed glycemia, insulin requirements, and carbohydrate 
      (CHO) needs during two consecutive days of prolonged cycling in type 1 diabetes 
      (T1D) adults using sensor-augmented insulin pump therapy. METHODS: Twenty adults 
      with well-controlled T1D and six healthy adults (for comparison) were enrolled. 
      Assessments were made during two consecutive days of cycling activities (30 miles 
      per day). On day 1 (D1), basal rates were reduced 50% and CHO intake was guided 
      by real-time continuous glucose monitoring (rtCGM) data to maintain a target 
      range (70-180 mg/dL). On day 2 (D2), basal insulin infusion was stopped for the 
      first hour of biking and resumed at a minimal rate during biking. Carbohydrate 
      intake one hour before, during, and ten minutes after biking was recorded. Times 
      within/below target range, glycemic variability, and mean glucose were calculated 
      from rtCGM data. RESULTS: Among 17 T1D participants who completed the study, mean 
      glucose levels at the start of cycling were slightly lower on D2 vs D1: 138 +/- 16 
      mg/dL and 122 +/- 16, respectively, P = NS. Type 1 diabetes participants achieved 
      near-normal glucose levels at the end of both cycling events; however, the 
      reduction in glucose was most notable at one hour into the event on D2 vs D1. 
      Carbohydrate intake was notably lower during D2 vs D1 with no difference in time 
      <54 mg/dL (both P = NS). CONCLUSIONS: Type 1 diabetes individuals using 
      rtCGM-augmented insulin pump therapy can safely engage in consecutive days of 
      prolonged aerobic exercise by significantly reducing insulin dosages with no 
      increase in CHO intake.
FAU - Muller-Korbsch, Michael
AU  - Muller-Korbsch M
AD  - MedVienna Arztezentrum, Austria.
FAU - Fruhwald, Lisa
AU  - Fruhwald L
AD  - 5th Medizinische Abteilung fur Endokrinologie und Rheumatologie, 
      Wilhelminenspital Austria, Vienna, Austria.
FAU - Heer, Michael
AU  - Heer M
AD  - University of Applied Sciences Technikum Wien, Vienna, Austria.
FAU - Fangmeyer-Binder, Maria
AU  - Fangmeyer-Binder M
AD  - 5th Medizinische Abteilung fur Endokrinologie und Rheumatologie, 
      Wilhelminenspital Austria, Vienna, Austria.
FAU - Reinhart-Mikocki, David
AU  - Reinhart-Mikocki D
AD  - 5th Medizinische Abteilung fur Endokrinologie und Rheumatologie, 
      Wilhelminenspital Austria, Vienna, Austria.
FAU - Fasching, Peter
AU  - Fasching P
AD  - 5th Medizinische Abteilung fur Endokrinologie und Rheumatologie, 
      Wilhelminenspital Austria, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191004
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 1/drug therapy
MH  - Exercise
MH  - Glycemic Control
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Insulin Infusion Systems
PMC - PMC7783009
OTO - NOTNLM
OT  - basal rate
OT  - carbohydrate
OT  - exercise
OT  - insulin pump
OT  - real-time continuous glucose monitoring
OT  - rtCGM
OT  - type 1 diabetes
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Michael Muller-Korbsch, Lisa Fruhwald, Michael Heer, 
      Maria Fangmeyer-Binder, and David Reinhart-Mikocki report no disclosures. Peter 
      Fasching has received fees for lectures and consultant activities for Eli Lilly 
      and Company and Novo Nordisk.
EDAT- 2019/10/05 06:00
MHDA- 2021/10/29 06:00
PMCR- 2020/10/04
CRDT- 2019/10/05 06:00
PHST- 2019/10/05 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2019/10/05 06:00 [entrez]
PHST- 2020/10/04 00:00 [pmc-release]
AID - 10.1177_1932296819879419 [pii]
AID - 10.1177/1932296819879419 [doi]
PST - ppublish
SO  - J Diabetes Sci Technol. 2021 Jan;15(1):127-133. doi: 10.1177/1932296819879419. 
      Epub 2019 Oct 4.